Luis Rico | Oncology | Editorial Board Member

Dr. Luis Rico | Oncology | Editorial Board Member

Managing Director | Hospital Aleman | Argentina

Dr. Luis Rico is a distinguished clinician–researcher at Hospital Alemán, Buenos Aires, renowned for his impactful contributions to urology, with a strong focus on endourology, advanced laser technologies, and minimally invasive surgical innovation. His work centers on improving procedural precision, optimizing perioperative outcomes, and enhancing patient safety in the management of complex urolithiasis. By integrating next-generation laser systems, cutting-edge endoscopic platforms, and refined surgical protocols, Dr. Rico continually advances evidence-based approaches that elevate standards of clinical care. With an active and growing academic footprint, he has authored numerous peer-reviewed publications addressing pivotal challenges in intrarenal surgery, flexible ureteroscopy, and comparative laser performance particularly evaluating modalities such as the Thulium Fiber Laser and HO:YAG systems. His research has expanded global understanding of operative efficiency, stone-free rates, laser–tissue dynamics, and postoperative recovery pathways. Dr. Rico collaborates extensively with international urology organizations, multidisciplinary surgical teams, and multicenter research networks, underscoring his commitment to shared scientific progress, surgical innovation, and clinical excellence. In addition to his research, he plays a key role in clinical training, contributes to multicenter trials, and advances patient-centered care through methodical, outcomes-driven practice. His scholarly contributions reflect a balanced blend of innovation, scientific rigor, and translational relevance, ensuring continued impact on the evolving landscape of urologic surgery and minimally invasive therapeutic strategies. Dr. Rico’s academic influence is further highlighted by his research metrics, which include 252 citations, 35 scientific documents, and an h-index of 9, reflecting both the quality and reach of his contributions to modern urological science.

Featured Publications

Rico, L., Blas, L., Álvarez Jaramillo, J., Filgueira, G., Soldano, J., & Contreras, P. (2025). Magneto Ho:YAG laser versus Thulium Fiber Laser for laser lithotripsy during flexible ureteroscopy with a flexible and navigable ureteral access sheath. International Urology and Nephrology.

Rico, L., Blas, L., Banda Ramos, L., Maqueda, M., Pizzarello, J., & Contreras, P. (2025). Thulium Fiber Laser versus Vapor Tunnel HO:YAG laser in retrograde intrarenal surgery: Which one has better laser ablation performance? World Journal of Urology.

Rico, L., Diaz-Zorita, V., Blas, L., Banda Ramos, L., Sabeh, P., & Contreras, P. (2025). Is the ablation stone efficacy and efficiency better with a flexible and navigable suction ureteric access sheath? World Journal of Urology.

Rico, L., Blas, L., Pizzarello, J., Banda-Ramos, L., & Contreras, P. (2024). Mini-endoscopic combined intrarenal surgery (mini-ECIRS) for complex urolithiasis. World Journal of Urology.

Rico, L., Maqueda, M., Blas, L., & Contreras, P. (2024). Anterograde placement of drug-coated balloon for ureteroileal anastomosis stricture. BMJ Case Reports.

Shahanavaj Khan | Cancer Science | Editorial Board Member

Assoc. Prof. Dr. Shahanavaj Khan | Cancer Science | Editorial Board Member

Associate Professor | Shri Ram College | India

Dr. Shahanavaj Khan is a distinguished researcher at King Saud University, Riyadh, specializing in cancer biology, pharmacology, and bioactive natural compounds. His work focuses on the anti-cancer and anti-inflammatory potential of plant-derived molecules, with particular emphasis on mechanisms involving apoptosis, Toll-Like Receptors, and microbiome-mediated cancer pathways. Dr. Khan employs advanced in-silico, in-vitro, and translational approaches to identify novel therapeutic targets and understand disease mechanisms, aiming to improve cancer diagnostics and treatment strategies. He has authored 54 publications in high-impact journals, contributing significantly to the understanding of prostate, lung, and other cancers, while integrating computational modeling with experimental validation. His research involves extensive collaborations with over 200 co-authors globally, demonstrating leadership in multidisciplinary oncology and pharmacology networks. Through his innovative studies on natural bioactive compounds and cancer therapeutics, Dr. Khan has contributed to the advancement of safer, more targeted treatment options, positively impacting patient care and public health. His scholarly work also underscores the importance of microbiome and receptor-mediated mechanisms in disease progression, bridging fundamental research with clinical applications. Dr. Khan’s academic influence and research productivity are reflected in his metrics 1,355 citations, 54 documents, and an h-index of 21.

Profiles: Scopus

Featured Publications

Khan, S., et al. (2025). Implication of Toll-Like Receptors in growth and management of health and diseases: Special focus as a promising druggable target to Prostate Cancer. [Review]. 7 citations.

Khan, S., et al. (2025). The implication of microbiome in lungs cancer: mechanisms and strategies of cancer growth, diagnosis and therapy. [Review]. 6 citations.

Khan, S., et al. (2025). Analysis of anti-cancer and anti-inflammatory activity in Typhonium flagelliforme rhizome extract by induction of apoptosis: An in-vitro study. Fitoterapia.

Dr. Wenhao Chen | Osteosarcoma | Best Researcher Award

Dr. Wenhao Chen | Osteosarcoma | Best Researcher Award

Zhejiang University School of Medicine Children’s Hospital National Clinical Research Center for Child Health | China

AUTHOR PROFILE

ORCID ID

SCOPUS

🎓 EARLY ACADEMIC PURSUITS

Dr. Wenhao Chen embarked on his medical journey at Peking University, where he completed his MD (2004–2012), laying a strong foundation in clinical and surgical sciences. His early exposure to academic rigor and translational research in one of China’s most prestigious institutions catalyzed his long-term interest in orthopedics and musculoskeletal oncology.

🏆 PROFESSIONAL ENDEAVORS

Currently serving as the Head of the Department of Orthopedics at the Children’s Hospital, Zhejiang University School of Medicine, Dr. Chen leads both clinical operations and scientific innovation. He completed his postdoctoral fellowship (2019–2020) at Massachusetts General Hospital (MGH), USA, a globally renowned center, where he honed his skills in translational and molecular orthopedics.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON OSTEOSARCOMA

Dr. Chen’s core research focus centers on osteosarcoma, Ewing sarcoma, and bone regeneration mechanisms. His work spans from genomic risk modeling to machine learning applications in prognosis prediction. Notably:

  • Identification of LARS as an essential gene in osteosarcoma proliferation via CRISPR-Cas9 screens (J Transl Med, 2022).

  • Developed prognostic nomograms and glycolysis-based risk scores to stratify osteosarcoma survival (J Orthop Res, 2022; Medicine, 2019).

  • Investigated radiotherapy sensitivity and metastatic prediction in osteosarcoma (J Cancer Res Clin Oncol, 2023).

His integration of molecular biology, AI modeling, and clinical data science reflects a translational approach that bridges lab discoveries with bedside applications.

🌍 IMPACT AND INFLUENCE

Dr. Chen’s body of work demonstrates multidisciplinary impact:

  • Oncology (osteosarcoma, Ewing sarcoma)

  • Orthopedic surgery innovations

  • Inhalation therapy for pulmonary fibrosis (J Transl Med, 2024)

  • Neural regeneration using viral gene therapy (Brain Res Bull, 2017)

His collaborations with top U.S. institutions and international teams exemplify his global research footprint and scientific leadership.

📖 ACADEMIC CITATIONS AND RECOGNITION

With 17 peer-reviewed publications, many in high-impact journals such as FASEB Journal, Journal of Translational Medicine, and Journal of Orthopaedic Research, Dr. Chen has amassed significant citations in the fields of oncology, orthopedics, and translational medicine, reflecting the clinical utility and scientific merit of his contributions.

🔮 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Chen’s vision for the future includes:

  • Developing non-invasive diagnostic models for early osteosarcoma detection

  • Expanding research into bone-tissue engineering and regeneration

  • Training future orthopedic surgeons and clinician-scientists with dual clinical and computational expertise

🌍CONCLUSION 

Dr. Wenhao Chen stands at the forefront of orthopedic science, blending clinical acumen, molecular insights, and computational power to reshape musculoskeletal disease treatment.

 

📊🔬NOTABLE PUBLICATION:

Title: The phosphatase CTDSPL2 promotes proliferation, invasion, metastasis and regorafenib resistance in osteosarcoma
Journal: Journal of Bone Oncology
Year: 2025

Title: Diminished GALNS activity in induced pluripotent stem cells of mucopolysaccharidosis IVA caused by compound p.S162Y and p.C165F mutation
Journal: QJM: An International Journal of Medicine
Year: 2025

Title: Chaperone‐mediated autophagy protects the bone formation from excessive inflammation through PI3K/AKT/GSK3β/β‐catenin pathway
Journal: The FASEB Journal
Year: 2024

Title: Outcomes of two-stage double-level rotational osteotomy in treating patients with congenital proximal radioulnar synostosis
Journal: World Journal of Pediatric Surgery
Year: 2023

Title: A novel risk score model based on glycolysis‐related genes and a prognostic model for predicting overall survival of osteosarcoma patients
Journal: Journal of Orthopaedic Research
Year: 2022